At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 96 enrolled
Drug / intervention
QVM149drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Open-label, Single Arm, 52-week Treatment Study to Assess the Safety of QVM149 in Japanese Patients With Asthma
In Brief
A Phase 3 clinical trial evaluating QVM149 for Asthma. Completed, enrolled 96 participants across 25 sites.
Detailed Summary
The purpose of this study is to provide long term safety data of QVM149 in Japanese patients with asthma for the registration of QVM149 in Japan.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAsthma
CountriesJapan
Collaborators--
Timeline
Phase 3CompletedFinished
2017201820192020202120222023202420252026
First PostedApr 2017
Enrollment StartApr 2017
Primary CompletionSep 2018
Study CompletionApr 2019
TodayJul 2026
First PostedApr 4, 2017
Enrollment StartApr 28, 2017
Primary CompletionSep 18, 2018
Study CompletionApr 8, 2019
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 9.2 years ago
Interventions
QVM149drug
QVM149 (indacaterol acetate/glycopyrronium bromide/mometasone furoate)